| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mastectomy | 48 | 2023 | 243 | 15.230 |
Why?
|
| Breast Neoplasms | 85 | 2023 | 2903 | 15.170 |
Why?
|
| Carcinoma, Ductal, Breast | 22 | 2022 | 157 | 7.760 |
Why?
|
| Carcinoma, Lobular | 18 | 2019 | 81 | 6.360 |
Why?
|
| Mastectomy, Segmental | 18 | 2023 | 93 | 4.380 |
Why?
|
| Surgeons | 11 | 2023 | 238 | 4.050 |
Why?
|
| Mammaplasty | 10 | 2023 | 107 | 3.270 |
Why?
|
| Prophylactic Mastectomy | 8 | 2020 | 13 | 3.060 |
Why?
|
| Neoadjuvant Therapy | 8 | 2019 | 318 | 2.970 |
Why?
|
| Neoplasm Staging | 25 | 2019 | 1939 | 2.710 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 7 | 2022 | 113 | 2.490 |
Why?
|
| Quality Indicators, Health Care | 5 | 2021 | 144 | 2.170 |
Why?
|
| Lymph Node Excision | 10 | 2021 | 217 | 2.110 |
Why?
|
| Receptors, Estrogen | 10 | 2022 | 384 | 2.090 |
Why?
|
| Surgical Oncology | 4 | 2020 | 27 | 2.050 |
Why?
|
| Sentinel Lymph Node Biopsy | 12 | 2021 | 68 | 2.030 |
Why?
|
| Radiation Oncology | 3 | 2021 | 119 | 2.000 |
Why?
|
| Female | 88 | 2023 | 44532 | 1.990 |
Why?
|
| Cancer Care Facilities | 3 | 2020 | 28 | 1.990 |
Why?
|
| Databases, Factual | 18 | 2018 | 814 | 1.930 |
Why?
|
| Middle Aged | 63 | 2023 | 25028 | 1.920 |
Why?
|
| Prognosis | 25 | 2020 | 3679 | 1.910 |
Why?
|
| Accreditation | 3 | 2019 | 60 | 1.890 |
Why?
|
| Time-to-Treatment | 3 | 2021 | 98 | 1.790 |
Why?
|
| Practice Guidelines as Topic | 7 | 2019 | 1036 | 1.770 |
Why?
|
| Guideline Adherence | 4 | 2018 | 223 | 1.670 |
Why?
|
| Follow-Up Studies | 21 | 2020 | 3640 | 1.640 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2020 | 1313 | 1.640 |
Why?
|
| Aged | 49 | 2023 | 18415 | 1.620 |
Why?
|
| Aged, 80 and over | 33 | 2018 | 6509 | 1.590 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2019 | 468 | 1.550 |
Why?
|
| Radiotherapy, Adjuvant | 9 | 2021 | 292 | 1.540 |
Why?
|
| Humans | 97 | 2023 | 86643 | 1.510 |
Why?
|
| Unilateral Breast Neoplasms | 4 | 2020 | 5 | 1.490 |
Why?
|
| Mastectomy, Subcutaneous | 2 | 2022 | 8 | 1.450 |
Why?
|
| Nipples | 6 | 2022 | 37 | 1.410 |
Why?
|
| Thoracic Wall | 2 | 2018 | 21 | 1.310 |
Why?
|
| Receptor, ErbB-2 | 5 | 2019 | 223 | 1.300 |
Why?
|
| Adult | 44 | 2023 | 25648 | 1.270 |
Why?
|
| Lymph Nodes | 4 | 2018 | 533 | 1.250 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2019 | 2438 | 1.240 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2020 | 582 | 1.170 |
Why?
|
| Decision Support Techniques | 2 | 2019 | 160 | 1.150 |
Why?
|
| Neoplasm Invasiveness | 9 | 2020 | 552 | 1.140 |
Why?
|
| Ergonomics | 3 | 2022 | 21 | 1.130 |
Why?
|
| United States | 26 | 2022 | 6672 | 1.110 |
Why?
|
| Combined Modality Therapy | 8 | 2021 | 1686 | 1.090 |
Why?
|
| Decision Making | 4 | 2019 | 642 | 1.070 |
Why?
|
| Breast | 6 | 2021 | 288 | 1.040 |
Why?
|
| Biomarkers, Tumor | 5 | 2019 | 1464 | 1.030 |
Why?
|
| Axilla | 11 | 2021 | 99 | 1.030 |
Why?
|
| Receptors, Progesterone | 6 | 2019 | 167 | 1.030 |
Why?
|
| Neoplasms, Second Primary | 3 | 2017 | 252 | 1.010 |
Why?
|
| Survival Rate | 12 | 2018 | 1863 | 1.000 |
Why?
|
| Retrospective Studies | 23 | 2020 | 8489 | 0.990 |
Why?
|
| Surveys and Questionnaires | 8 | 2023 | 2501 | 0.960 |
Why?
|
| Attitude of Health Personnel | 4 | 2023 | 636 | 0.920 |
Why?
|
| Brachytherapy | 2 | 2014 | 119 | 0.880 |
Why?
|
| Carcinoma | 2 | 2017 | 436 | 0.880 |
Why?
|
| Breast Neoplasms, Male | 1 | 2022 | 30 | 0.860 |
Why?
|
| Organ Sparing Treatments | 2 | 2019 | 38 | 0.840 |
Why?
|
| Medical Overuse | 2 | 2019 | 36 | 0.830 |
Why?
|
| Neoplasm Grading | 10 | 2018 | 357 | 0.800 |
Why?
|
| Oncologists | 1 | 2021 | 36 | 0.760 |
Why?
|
| Quality of Health Care | 3 | 2018 | 380 | 0.760 |
Why?
|
| Young Adult | 13 | 2023 | 5976 | 0.710 |
Why?
|
| Burnout, Professional | 1 | 2021 | 94 | 0.690 |
Why?
|
| Healthcare Disparities | 2 | 2015 | 371 | 0.690 |
Why?
|
| Lymphatic Metastasis | 7 | 2018 | 486 | 0.690 |
Why?
|
| Age Factors | 9 | 2018 | 1851 | 0.680 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2017 | 150 | 0.670 |
Why?
|
| Stereotaxic Techniques | 1 | 2019 | 69 | 0.670 |
Why?
|
| Prophylactic Surgical Procedures | 2 | 2015 | 7 | 0.660 |
Why?
|
| Image-Guided Biopsy | 1 | 2019 | 66 | 0.660 |
Why?
|
| Patient Selection | 6 | 2019 | 685 | 0.650 |
Why?
|
| Patient Satisfaction | 4 | 2016 | 455 | 0.650 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 316 | 0.640 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 301 | 0.640 |
Why?
|
| Reoperation | 5 | 2015 | 597 | 0.630 |
Why?
|
| Consensus | 2 | 2016 | 335 | 0.630 |
Why?
|
| Patient Care | 1 | 2019 | 100 | 0.620 |
Why?
|
| Radiography, Interventional | 1 | 2019 | 150 | 0.620 |
Why?
|
| Patient Transfer | 1 | 2018 | 91 | 0.620 |
Why?
|
| Genes, BRCA2 | 3 | 2016 | 160 | 0.620 |
Why?
|
| Patient Reported Outcome Measures | 4 | 2020 | 166 | 0.620 |
Why?
|
| Genes, BRCA1 | 3 | 2016 | 192 | 0.610 |
Why?
|
| Hospitals, Low-Volume | 1 | 2017 | 18 | 0.610 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2017 | 238 | 0.600 |
Why?
|
| Hospitals, High-Volume | 1 | 2017 | 35 | 0.600 |
Why?
|
| Radiotherapy, Conformal | 1 | 2017 | 83 | 0.590 |
Why?
|
| Patient Preference | 4 | 2019 | 105 | 0.580 |
Why?
|
| Logistic Models | 7 | 2017 | 1186 | 0.570 |
Why?
|
| Postoperative Complications | 7 | 2016 | 2207 | 0.560 |
Why?
|
| Societies, Medical | 2 | 2019 | 572 | 0.550 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 508 | 0.530 |
Why?
|
| Prospective Studies | 8 | 2022 | 4213 | 0.510 |
Why?
|
| Estrogen Receptor alpha | 2 | 2013 | 144 | 0.500 |
Why?
|
| Quality of Life | 4 | 2019 | 1585 | 0.500 |
Why?
|
| Adolescent | 8 | 2023 | 8981 | 0.460 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 351 | 0.460 |
Why?
|
| Elective Surgical Procedures | 1 | 2014 | 116 | 0.450 |
Why?
|
| Length of Stay | 3 | 2015 | 702 | 0.440 |
Why?
|
| Receptors, Notch | 2 | 2010 | 120 | 0.430 |
Why?
|
| Cross-Sectional Studies | 4 | 2021 | 1621 | 0.430 |
Why?
|
| Melanoma | 2 | 2009 | 459 | 0.420 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2013 | 173 | 0.420 |
Why?
|
| Skin Neoplasms | 2 | 2009 | 546 | 0.410 |
Why?
|
| Registries | 1 | 2014 | 702 | 0.390 |
Why?
|
| Workload | 2 | 2022 | 128 | 0.380 |
Why?
|
| Operating Rooms | 2 | 2022 | 126 | 0.380 |
Why?
|
| Receptor, Notch1 | 2 | 2010 | 85 | 0.380 |
Why?
|
| Patient Readmission | 1 | 2014 | 329 | 0.370 |
Why?
|
| Gelatin Sponge, Absorbable | 1 | 2008 | 3 | 0.340 |
Why?
|
| Patients | 2 | 2023 | 100 | 0.340 |
Why?
|
| Breast Diseases | 1 | 2008 | 97 | 0.320 |
Why?
|
| Socioeconomic Factors | 3 | 2016 | 567 | 0.320 |
Why?
|
| Quality Control | 2 | 2019 | 117 | 0.310 |
Why?
|
| Breast Implantation | 3 | 2016 | 12 | 0.300 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2010 | 645 | 0.300 |
Why?
|
| Calcinosis | 1 | 2008 | 224 | 0.300 |
Why?
|
| Pilot Projects | 3 | 2019 | 839 | 0.290 |
Why?
|
| SEER Program | 3 | 2017 | 190 | 0.280 |
Why?
|
| Risk Factors | 6 | 2019 | 5417 | 0.280 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2017 | 865 | 0.270 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 999 | 0.270 |
Why?
|
| Risk Assessment | 4 | 2020 | 2261 | 0.260 |
Why?
|
| Health Care Surveys | 2 | 2018 | 278 | 0.260 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3362 | 0.260 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 859 | 0.250 |
Why?
|
| Referral and Consultation | 2 | 2019 | 328 | 0.250 |
Why?
|
| Biopsy | 3 | 2014 | 1163 | 0.230 |
Why?
|
| Self Concept | 1 | 2023 | 133 | 0.220 |
Why?
|
| Time Factors | 5 | 2016 | 5210 | 0.220 |
Why?
|
| Radiotherapy Dosage | 2 | 2014 | 468 | 0.220 |
Why?
|
| Pandemics | 4 | 2022 | 740 | 0.220 |
Why?
|
| Cohort Studies | 4 | 2018 | 2767 | 0.190 |
Why?
|
| Male | 8 | 2022 | 40965 | 0.190 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 1384 | 0.190 |
Why?
|
| Mammography | 2 | 2017 | 463 | 0.180 |
Why?
|
| Betacoronavirus | 2 | 2020 | 258 | 0.180 |
Why?
|
| Personnel Selection | 1 | 2020 | 59 | 0.180 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 1019 | 0.180 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2018 | 237 | 0.180 |
Why?
|
| Health Resources | 1 | 2020 | 76 | 0.180 |
Why?
|
| Body Image | 1 | 2019 | 76 | 0.170 |
Why?
|
| Triage | 1 | 2020 | 108 | 0.170 |
Why?
|
| Specialties, Surgical | 1 | 2020 | 64 | 0.170 |
Why?
|
| Fear | 1 | 2019 | 78 | 0.170 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2022 | 275 | 0.170 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 108 | 0.170 |
Why?
|
| Treatment Outcome | 5 | 2018 | 7993 | 0.170 |
Why?
|
| Interviews as Topic | 1 | 2020 | 319 | 0.170 |
Why?
|
| Breast Implants | 2 | 2016 | 23 | 0.170 |
Why?
|
| User-Computer Interface | 1 | 2020 | 185 | 0.170 |
Why?
|
| Anxiety | 1 | 2021 | 287 | 0.170 |
Why?
|
| Video Recording | 1 | 2019 | 190 | 0.170 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2018 | 5 | 0.160 |
Why?
|
| Databases as Topic | 1 | 2018 | 92 | 0.160 |
Why?
|
| Emotions | 1 | 2021 | 341 | 0.160 |
Why?
|
| Patient Participation | 1 | 2019 | 216 | 0.150 |
Why?
|
| Telemedicine | 1 | 2020 | 169 | 0.150 |
Why?
|
| Patient Compliance | 1 | 2018 | 227 | 0.150 |
Why?
|
| Heterozygote | 2 | 2016 | 365 | 0.150 |
Why?
|
| Choice Behavior | 1 | 2018 | 160 | 0.150 |
Why?
|
| Sleep | 1 | 2021 | 444 | 0.140 |
Why?
|
| Odds Ratio | 1 | 2018 | 678 | 0.140 |
Why?
|
| Surgical Wound Infection | 2 | 2015 | 184 | 0.140 |
Why?
|
| Ultrasonography, Mammary | 1 | 2017 | 82 | 0.140 |
Why?
|
| Disease Management | 1 | 2018 | 327 | 0.140 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2017 | 176 | 0.140 |
Why?
|
| Esthetics | 1 | 2016 | 44 | 0.140 |
Why?
|
| Illinois | 1 | 2017 | 462 | 0.140 |
Why?
|
| Watchful Waiting | 1 | 2016 | 60 | 0.140 |
Why?
|
| Molecular Typing | 1 | 2015 | 17 | 0.140 |
Why?
|
| Comprehension | 1 | 2016 | 79 | 0.130 |
Why?
|
| Europe | 1 | 2016 | 309 | 0.130 |
Why?
|
| Remission Induction | 1 | 2017 | 722 | 0.130 |
Why?
|
| Neoplasms | 2 | 2022 | 2898 | 0.130 |
Why?
|
| Pharyngectomy | 1 | 2015 | 8 | 0.130 |
Why?
|
| Population Surveillance | 1 | 2016 | 219 | 0.130 |
Why?
|
| Immunohistochemistry | 2 | 2010 | 1753 | 0.130 |
Why?
|
| Counseling | 1 | 2016 | 145 | 0.130 |
Why?
|
| Physicians | 2 | 2019 | 673 | 0.130 |
Why?
|
| Carcinoma in Situ | 1 | 2015 | 53 | 0.120 |
Why?
|
| Selection Bias | 1 | 2014 | 37 | 0.120 |
Why?
|
| Linear Models | 1 | 2015 | 421 | 0.120 |
Why?
|
| Chemoradiotherapy | 1 | 2017 | 301 | 0.120 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 1056 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2018 | 1805 | 0.120 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 938 | 0.120 |
Why?
|
| Incidence | 2 | 2017 | 1577 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 454 | 0.120 |
Why?
|
| Adipokines | 1 | 2013 | 19 | 0.120 |
Why?
|
| Receptor, Notch4 | 2 | 2010 | 5 | 0.120 |
Why?
|
| Insurance, Health | 1 | 2014 | 160 | 0.120 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2015 | 118 | 0.110 |
Why?
|
| Robotic Surgical Procedures | 1 | 2018 | 267 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 860 | 0.110 |
Why?
|
| Fatty Acids | 1 | 2013 | 130 | 0.110 |
Why?
|
| Surgical Flaps | 1 | 2015 | 241 | 0.110 |
Why?
|
| Venous Thromboembolism | 1 | 2015 | 153 | 0.110 |
Why?
|
| Adipose Tissue | 1 | 2013 | 240 | 0.100 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 394 | 0.100 |
Why?
|
| Models, Biological | 1 | 2018 | 1749 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2705 | 0.090 |
Why?
|
| Jagged-1 Protein | 1 | 2010 | 11 | 0.090 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2010 | 12 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 1197 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 1052 | 0.090 |
Why?
|
| Calcium-Binding Proteins | 1 | 2010 | 115 | 0.090 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 2262 | 0.090 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 179 | 0.090 |
Why?
|
| False Positive Reactions | 1 | 2008 | 216 | 0.080 |
Why?
|
| Receptor Cross-Talk | 1 | 2008 | 33 | 0.080 |
Why?
|
| Early Detection of Cancer | 2 | 2022 | 394 | 0.080 |
Why?
|
| Hemostatics | 1 | 2008 | 56 | 0.080 |
Why?
|
| Quality Improvement | 2 | 2022 | 428 | 0.080 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2008 | 70 | 0.080 |
Why?
|
| Interferon-alpha | 1 | 2009 | 233 | 0.080 |
Why?
|
| Biopsy, Needle | 1 | 2008 | 235 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2015 | 1076 | 0.080 |
Why?
|
| Hyperplasia | 1 | 2008 | 148 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 364 | 0.080 |
Why?
|
| Cancer Vaccines | 1 | 2009 | 156 | 0.080 |
Why?
|
| Immunologic Factors | 1 | 2009 | 170 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 178 | 0.070 |
Why?
|
| Obesity | 1 | 2013 | 963 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2012 | 1981 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2008 | 912 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2011 | 1204 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 1991 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2010 | 1196 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 1673 | 0.060 |
Why?
|
| Mutation | 1 | 2014 | 3968 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 2 | 2013 | 303 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2023 | 256 | 0.050 |
Why?
|
| Organizational Innovation | 1 | 2020 | 41 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2013 | 1041 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2023 | 535 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 297 | 0.040 |
Why?
|
| Fees and Charges | 1 | 2018 | 14 | 0.040 |
Why?
|
| Hospital Charges | 1 | 2018 | 29 | 0.040 |
Why?
|
| Sentinel Lymph Node | 1 | 2018 | 15 | 0.040 |
Why?
|
| Propensity Score | 1 | 2018 | 136 | 0.040 |
Why?
|
| Mass Screening | 1 | 2022 | 618 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2018 | 334 | 0.040 |
Why?
|
| Urologic Surgical Procedures | 1 | 2018 | 146 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2017 | 289 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2017 | 221 | 0.030 |
Why?
|
| Chicago | 1 | 2020 | 1379 | 0.030 |
Why?
|
| ROC Curve | 1 | 2018 | 752 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2013 | 1578 | 0.030 |
Why?
|
| Prostatectomy | 1 | 2018 | 471 | 0.030 |
Why?
|
| Self Report | 1 | 2016 | 288 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2015 | 111 | 0.030 |
Why?
|
| Communication | 1 | 2018 | 441 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2015 | 157 | 0.030 |
Why?
|
| Lipase | 1 | 2013 | 22 | 0.030 |
Why?
|
| Serpins | 1 | 2013 | 29 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2015 | 331 | 0.030 |
Why?
|
| Nerve Growth Factors | 1 | 2013 | 63 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 674 | 0.030 |
Why?
|
| Leptin | 1 | 2013 | 105 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 610 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2012 | 64 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2012 | 96 | 0.030 |
Why?
|
| Eye Proteins | 1 | 2013 | 128 | 0.030 |
Why?
|
| Contraindications | 1 | 2012 | 72 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2012 | 348 | 0.030 |
Why?
|
| Sepsis | 1 | 2015 | 306 | 0.020 |
Why?
|
| Comorbidity | 1 | 2015 | 943 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2013 | 770 | 0.020 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2008 | 40 | 0.020 |
Why?
|
| Estradiol | 1 | 2008 | 252 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2008 | 458 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 547 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2008 | 790 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 1047 | 0.020 |
Why?
|
| Mice | 1 | 2008 | 11352 | 0.010 |
Why?
|
| Animals | 1 | 2008 | 26582 | 0.010 |
Why?
|